

Supplementary Materials

Integrative single-cell and bulk RNA-seq analysis in human retina identified cell type-specific composition and gene expression changes for age-related macular degeneration

Yafei Lyu^{1,*}, Randy Zauhar^{2,*}, Nico Dana³, Christianne E. Strang⁴, Kui Wang¹, Shanrun Liu⁵, Zhen Miao¹, Naifei Pan⁶, Paul Gamlin⁷, James A. Kimble⁷, Jeffrey D. Messinger⁷, Christine A. Curcio⁷, Dwight Stambolian^{3,§}, Mingyao Li^{1,§}

¹Department of Biostatistics, Epidemiology and Informatics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA; ²Department of Chemistry and Biochemistry, The University of the Sciences in Philadelphia, Philadelphia, PA 19104, USA; ³Dept of Ophthalmology and Human Genetics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA; ⁴Department of Psychology, University of Alabama at Birmingham, Birmingham, AL 35294, USA; ⁵Department of Biochemistry and Molecular Genetics, University of Alabama at Birmingham, Birmingham, AL 35294, USA; ⁶Department of Computer and Information Science, University of Pennsylvania, PA 19104, USA; ⁷Department of Ophthalmology and Visual Sciences, University of Alabama at Birmingham, Birmingham, AL 35294, USA.

* Equal contribution

§ Correspondence to mingyao@penmedicine.upenn.edu or stamboli@penmedicine.upenn.edu

Supplementary Notes

Supplementary Note 1. scRNA-seq sample processing and data generation

Supplementary Note 2. scRNA-seq data clustering and cell type assignment

Supplementary Note 3. Identification of cell type-specific marker genes

Supplementary Note 4. Bulk RNA-seq sample processing and data generation

Supplementary Note 5. Comparison of UAB and EyeGEx bulk RNA-seq data

Supplementary Note 6. AMD associated DEGs are tend to be cell type-specific

Supplementary Note 7. Comparison of ctDEGs effect across disease stages and regions

Supplementary Figures

Supplementary Fig. 1. Overview and quality control of scRNA-seq data

Supplementary Fig. 2. Similarity in expression pattern across cell clusters

Supplementary Fig. 3. Identified cell types from scRNA-seq data

Supplementary Fig. 4. Expression of AMD risk genes across cell types and retina regions

- 37 Supplementary Fig. 5. Similarity of bulk RNA-seq data across datasets and conditions
- 38 Supplementary Fig. 6. Cell type proportion changes across AMD stages
- 39 Supplementary Fig. 7. DE fold change for cell type markers in bulk RNA-seq data level
- 40 Supplementary Fig. 8. Comparison of ctDEGs effect between AMD stages
- 41 Supplementary Fig. 9. Comparison of ctDEGs effect between retina regions
- 42 Supplementary Fig. 10. Comparison of ct DEGs effect between periphery retina datasets.

43

44 **Supplementary Data**

- 45 Supplementary Data 1. Cell type-specific gene markers detected from the scRNA-seq data.
- 46 Supplementary Data 2. Single-cell level expression patterns of AMD risk genes.
- 47 Supplementary Data 3. Differential expression results for the UAB bulk RNA-seq data.
- 48 Supplementary Data 4. ctDEGs identified in the EyeGEx bulk RNA-seq data.
- 49 Supplementary Data 5. GO enrichment result for ctDEGs in the EyeGEx bulk RNA-seq data.
- 50 Supplementary Data 6. ctDEGs identified in the UAB bulk RNA-seq data.
- 51 Supplementary Data 7. GO enrichment result for ctDEGs in the UAB bulk RNA-seq data.
- 52 Supplementary Data 8. Known retina cell type markers.

53

54 **Supplementary Note 1. scRNA-seq sample processing and data generation**

55 **Eye collection protocol.** Donor eyes from two Caucasian male donors, aged 78 and 90, were obtained
56 from Advancing Sight Network (formerly Alabama Eye Bank) within 6 hours postmortem. Neither donor
57 had a known history of retinal disease, head or ocular trauma, significant refractive error, neurological
58 disease, diabetes, or uncontrolled hypertension.

59

60 **Dissection and dissociation of retina.** Following removal of the anterior chamber and vitreous, the
61 eyecup was immersed in oxygenated Ames media. Relief cuts were made in the posterior eyecup to
62 expose the retinal tissue and 8 mm punches were obtained from macular retina and temporal (peripheral)
63 retina and carefully isolated from the combined retinal pigment epithelium and choroid tissue. The
64 isolated neurosensory retina was dissociated with activated papain (Worthington Biochemical Corp.) as
65 previously optimized to obtain a high percentage of viable retinal cells¹. After dissociation, magnetic
66 bead-based removal of dead cells (Miltenyi Biotech) was used to reach the optimum target for viability
67 of 85-95% per sample. Viability was determined by FACS sort or by staining an aliquot of the dissociated
68 cells with trypan blue, 0.4% (Sigma-Aldrich).

69


70 **Single cell transcriptome library preparation and sequencing.** Single cell transcriptome libraries
71 were prepared by using 10xGenomics Single Cell 3' biased v2 kit according to the company's manual.
72 The constructed single cell libraries were sequenced by HiSeq 2000 sequencer (Illumina, Inc., San
73 Diego, CA, USA) with total reads per cell targeted for a minimum of 50,000.

74

75 **Preprocessing of scRNA-seq data.** For each sample replicate, we performed initial quality control
76 using Cell Ranger (Version 2.1.0). For macular retina samples, we initially obtained a 33,694 genes by
77 48,800 cells count matrix. For peripheral retina samples, we obtained a 33,694 genes by 59,222 cells
78 count matrix. Then, we further filtered the data using Seurat (version 2.3.4)². A cell was retained in
79 downstream analyses if it meets the following criteria: (1) More than 200 genes are detected; (2) The
80 proportion of the transcript counts from mitochondrial encoded genes is less than 25%; (3) Total number
81 of UMIs is between 500 and 10,000. This resulted in 33,694 genes across 92,386 cells (macula: 36,959;
82 periphery: 55,426), which were used for analysis shown in **Supplementary Fig. 1**.

83

84



85

86

87

88

89 **Supplementary Fig. 1. Overview and quality control of scRNA-seq data.**

90 **(a)** Bar graph showing the number of cells for the four filtered scRNA-seq samples (two samples for
 91 macular retina and two samples for peripheral retina). **(b)** Violin plots showing the distribution of the
 92 number of UMIs per cell (left), number of genes per cell (middle) and percentage of mitochondrial genes
 93 per cell for the four scRNA-seq samples. **(c)** t-SNE projections of the scRNA-seq data. Color labels cells
 94 from different samples. The cells are randomly mixed, indicating batch effect was removed in clustering.
 95 **(d)** Bar plots showing proportions of identified cell types from the scRNA-seq data across the two retina
 96 regions.

97

98 **Supplementary Note 2. scRNA-seq data clustering and cell type assignment**


99 To identify cell types in the scRNA-seq data, we clustered cells into transcriptionally similar groups using
100 DESC³ (**Methods**). Initially, we obtained 18 cell clusters but decided to continue with 16 cell clusters
101 because 2 cell clusters had less than 50 cells. We annotated these 16 cell clusters with cell type labels
102 by examining expression patterns of known retina cell type markers (**Supplementary Data 8**). We
103 identified six bipolar subtypes. To examine these 16 cell clusters further, we performed pairwise
104 differential expression analysis among 16 cell clusters using *FindMarkers* from the Seurat package. We
105 enabled the Wilcoxon test by specifying `test.use = "wilcox"` and all other parameters were set as default,
106 and used adjusted p-value<0.05, fold-change>2 as threshold to determine significant DEGs between
107 each pair of cell clusters. We detected a considerable number of DEGs between each pair of cell clusters,
108 except the pairwise analysis among the 6 cell clusters labeled as bipolar (**Supplementary Fig. 2**).
109 Therefore, we maintained these 6 clusters as bipolar cell subtypes. In total, we determined 11 major cell
110 types. **Supplementary Fig. 3** shows the expression patterns of representative known cell type markers
111 across the 11 identified cell types and the hierarchical similarities of these cell types.

112

113

114

115





116

117

118

119 **Supplementary Fig. 2. Similarity in expression pattern across cell clusters.** The heatmap shows
 120 the number of significant DEGs detected between each pair of cell clusters. Sixteen cell clusters were
 121 identified using DESC and six of them were labeled as bipolar subtypes (BC1-BC6). The annotation in
 122 tiles show the exact number of significant DEGs for each pairwise differential expression analysis

123



124

125

126 **Supplementary Fig. 3. Identified cell types from scRNA-seq data.** (a) Dot plots showing
 127 expression pattern of known gene markers across cell types identified (**Supplementary Data 8**). The
 128 dot plot was generated using *Dotplot* in R Seurat package. The size of the dots represents percentage
 129 of cells that expressed gene markers while color shows average expression levels of gene markers.

130 (b) The dendrogram shows the hierarchy of identified cell types. Hierarchical clustering analysis was
 131 performed on the mean expression for all genes across cells within each of the cell types.

132 **Supplementary Note 3. Identification of cell type-specific marker genes**

133 To determine if a gene is preferentially expressed in a given cell type, we performed differential
134 expression analysis to test whether a gene has a significantly higher expression in the given cell type
135 than all other cell types. The analysis was implemented using the *FindMarkers* function in Seurat R
136 package. We used the Wilcoxon test for the differential expression analysis by specifying `test.use =`
137 `"wilcox"` and all other parameters were set as default. Then, the significant (adjusted P value<0.05,
138 positive fold change>2) DEGs for each of the cell types were defined as cell type-specific genes. Note
139 that it is possible that a gene is specific to multiple cell types, although such cases are rare.


140

141 We performed the cell type-specific markers identification by combining data from two retina regions, as
142 well as using macula and periphery data separately. Identified cell type-specific genes can be found in
143 **Supplementary Data 1**.

144

145

146



147

148

149

150

151 **Supplementary Fig. 4. Expression of AMD risk genes across cell types and retina regions.** Dot
 152 plots showing expression patterns of AMD risk genes (top: GWAS AMD gene, bottom: TWAS target
 153 genes) across cell types and retina regions. The dot plot was generated using *Dotplot* in R Seurat
 154 package. The size of the dots represents percentage of cells that expressed gene markers while color
 155 shows average expression levels of gene markers.

156

157 **Supplementary Note 4. UAB bulk tissue processing and data generation**

158 **Histopathological analysis of UAB samples.** The Institutional Review Board at UAB approved the
159 use of human tissues in this study. This study utilized 8 pairs of eyes from non-diabetic Caucasian
160 donors 69-95 yr of age ($84.73 \text{ yr} \pm 5.53 \text{ yr}$; 8 males and 7 females) at a death-to-preservation interval
161 of $< 6 \text{ hr}$. Ocular health histories were not available. Eyes were opened by eye bank recovery personnel
162 using an 18 mm diameter corneal trephine, followed by a snip to the iris to facilitate penetrate of
163 preservatives into the fundus. Preservatives were RNAlater (Qiagen) for the Left Eye and 2%
164 glutaraldehyde and 1% paraformaldehyde in 0.1M phosphate buffer for the Right Eye, both at 4°C . Left
165 Eyes were shipped on wet ice via overnight courier to University of Pennsylvania where they were
166 processed upon arrival.

167

168 Maculopathy status of Right Eyes was assessed at UAB by a 3-component protocol. Eyes underwent
169 multimodal ex vivo imaging of excised 8-mm diameter macular punches using digital color photography
170 and spectral domain optical coherence tomography volume scans (SD-OCT; Spectralis, Heidelberg
171 Engineering) with a custom tissue holder (co-author JDM). They also underwent internal globe
172 examination using a dissecting scope (Nikon SMZ-U) with oblique trans- and epi-illumination in
173 consultation with an MD medical retina specialist (co-author JAK). Finally, eyes were submitted for
174 histopathology using macula-wide high-resolution sections. Macular punches including retina, RPE,
175 choroid, and sclera were then post-fixed in osmium tannic acid paraphenylenediamine to accentuate
176 neutral lipid-rich lesions associated with age-related macular degeneration (AMD)^{4,5}. Sections $0.8 \mu\text{m}$
177 in thickness through the rod-free foveola and the rod-rich perifovea at $2000 \mu\text{m}$ superior to the fovea
178 were stained with toluidine blue, examined, and annotated.

179

180 The definition of AMD used in this study⁶ was the presence of one large druse ($>125 \mu\text{m}$ in diameter) in
181 the macula or severe RPE changes in the setting of at least one druse or continuous basal linear deposit,
182 with or without the presence of neovascularization and its sequelae. Eyes with geographic atrophy had
183 at least one region $250 \mu\text{m}$ in diameter lacking a continuous RPE layer (but possibly containing
184 'dissociated' RPE⁷. Unremarkable eyes lacking characteristics of AMD or other chorioretinal disease as
185 discernable in either histology or ex vivo imaging served as comparison eyes.

186

187 The use of fellow eyes optimally preserved for RNA-seq and for histopathology in this study is a limitation,
188 because two eyes of one individual may be at different disease severity. We feel that this limitation is
189 manageable, because it was recently found in a population-based cohort that was observed for 20 years,
190 AMD severity in one eye was found to largely track AMD severity in the fellow eye at all stages of the
191 disease⁸. This published study also found a $<10\%$ chance of lifetime occurrence of asymmetry >2 steps
192 on the grading scale for color fundus photography.

193

194 **Dissection and dissociation of retina.** Macula and periphery were dissected from retina resulting in
195 two samples per eye. The tissues were isolated at the macula and periphery using a circular 10-mm
196 biopsy punch.

197

198 **UAB data library preparation and sequencing.** RNA for the eye tissues was extracted using the
199 AllPrep DNA/RNA Mini Kit (Qiagen). Extracted RNA samples underwent quality control assessment
200 using R6K Screen Tape on a 2200 Tape Station (Agilent, Santa Clara, CA, USA) and were quantified
201 using Qubit 2.0 Fluorimeter from Life Technologies (Grand Island, NY). All RNA samples selected for
202 sequencing had an RNA integrity number of ≥ 8 . Strand-specific RNA library was prepared from 100 ng
203 totalRNA using the Encore Complete RNA-Seq library kit (Nugen Technologies, Inc., San Carlos, CA,
204 USA) according to the manufacturer's protocol. RNA sequencing was performed at the Center for
205 Applied Genomics at the Children's Hospital of Philadelphia per standard protocols. The prepared
206 libraries were clustered and then sequenced using HiSeq 2000 sequencer (Illumina, Inc., San Diego,
207 CA, USA) with four RNA-seq libraries per lane (2×101 -bp paired-end reads).

208

209 **Preprocessing of bulk tissue data.**

210 The RNA-Seq data were aligned to the hg38 reference genome using GSNAP (version 2016-06-30)
211 with known splice sites (SNP file build 147) taken into account. In order to eliminate mapping errors and
212 reduce potential mapping ambiguity owing to homologous sequences, several filtering steps were
213 applied. Specifically, we required the mapping quality score of ≥ 30 for each read, reads from the same
214 pair were mapped to the same chromosome with expected orientations and the mapping distance
215 between members of the read pair was 200,000 bp. Quality control analysis of the aligned data was
216 performed using program RNA-SeQC. All subsequent analyses were based on filtered alignment files.

217

218 Per-gene counts were generated from the GSNAP alignments using the HTSeq-count program (version
219 0.6.0) using default 'union' mode and the HG38 reference genome.

220

221

222

223

224

225 **Supplementary Note 5. Comparison of bulk tissue and EyeGEx bulk RNA-seq data**

226 Here we examined similarity of overall expression pattern across datasets and retinal regions. We
227 calculated mean read counts within each datasets/conditions for genes that existed in both datasets.
228 Then pairwise Pearson correlation were calculated upon the \log_2 scaled mean read counts
229 (**Supplementary Fig. 5**). In both UAB and EyeGEx data, we observed that the overall expression
230 pattern are similar (Spearman correlation >0.95) across all conditions for the periphery region. Even
231 across different datasets, the overall expression of retina periphery are similar (Pearson
232 correlation >0.84). In contrast, the macular region shows a distinct expression pattern compared to the
233 periphery. In the UAB datasets, such difference is highlighted when comparing macula and periphery
234 within the same condition (Pearson correlation <0.67). Further, the expression of macula under late AMD
235 seems to be an outlier, distanced from all others, suggesting a drastic change in expression.

236


237

238

239

240

241



242

243


244

245 **Supplementary Fig. 5. Similarity of bulk RNA-seq data across datasets and conditions.** The
 246 heatmap shows the similarity (Pearson correlation) in overall expression pattern across UAB and
 247 EyeGEx datasets and conditions. Pearson correlation was calculated using log scales read counts
 248 between each pair of samples. Only genes that existed in both datasets were considered in the analysis.

249

250

251




252

253

254

255 **Supplementary Fig. 6. Cell type proportion changes across AMD stages.** The bar graphs show
 256 proportion changes of cell type across different AMD stages. Color shows the direction of the changes
 257 (red: decreasing, green: increasing). **(a)** Changes in cell type proportions in EyeGEx data when
 258 comparing MGS 2, 3, and 4 to MGS 1. **(b)** Changes in cell type proportions in UAB data when comparing
 259 early and late AMD to normal.

260



261

262

263

264 **Supplementary Fig. 7. DE fold change for cell type markers in bulk RNA-seq data level.** The
 265 histograms show the distribution of DE fold change for cell type markers in bulk RNA-seq data level (top:
 266 EyeGEx periphery, mid: UAB periphery, bottom: UAB macula). Red vertical line labels the mean of fold
 267 changes for each of the cell types while black vertical line labels $x = 0$ as comparison. For each of the
 268 cell type, genes that specifically expressed in the cell type were identified using scRNA-seq data. Then
 269 DE analysis were performed for these genes using bulk RNA-seq data. The calculated fold changes

270 from the DE analysis were used to calibrate expression data in order to detected cell type-specific DEGs
271 (**Methods**).
272

273 **Supplementary Note 6. Region- and cell type-specificity of AMD associated DEGs**

274 We counted the cell type specific genes (**Supplementary Note 3**) among identified DEGs using UAB
275 data. For macula, 3 among 21 (14.2%) DEGs between AMD early and Normal, 1202 among 9772
276 (12.3%) DEGs between AMD late and Normal show cell type-specificity. For periphery, 10 among 169
277 (6.0%) DEGs between AMD early and Normal, 179 among 1214 (14.7%) DEGs between AMD late and
278 Normal show cell type-specificity.

279

280

281

282

283 **Supplementary Note 7. Comparison of ctDEGs effect across disease stages, regions and**
284 **datasets**

285 To investigate cell type-specific AMD impact, we identified genes that are differentially expressed in
286 particular cell types (**Methods**). These ctDEGs reflect the AMD response of different retinal cell types.
287 It is possible that the level of such response are region-specific or relate to disease progression. To test
288 our hypothesis, we examined linear relationship of log fold change between DE tests conducted for
289 different AMD stages and retinal regions.

290

291 **Enhanced AMD response along with disease progression.** To compare the cell type specific AMD
292 response between different disease stages, for each of the cell types, we examined linear relationship
293 of log fold changes between two DE tests, MGS 2 vs. MGS1 and MGS 4 vs. MGS1, performed using
294 EyeGEx data:

295
$$y_g^j = \beta^j x_g^j + \varepsilon_g^j \quad g \in G_j$$

296 where y_g^j is log fold changes of gene g between MGS 4 vs. MGS1 at cell type j , while x_g^j is the log fold
297 change between MGS 2 vs. MGS1. The β^j reflects the overall changes of DE effect size between tests
298 for cell type j . In the analysis, p values were adjusted for the number of cell types using BH method. For
299 each of the cell types, we reported estimated β and its significance in the **Supplementary Fig. 8**. We
300 identified significant β (adjusted P value < 0.05) for amacrine, astrocytes, cone, endothelium, microglia,
301 muller and pericytes. In cone ($\beta=0.51$), Müller ($\beta=0.33$) and pericytes ($\beta=0.61$), much larger DE fold
302 changes were found between MGS 4 vs. MGS1 indicating an increased level of AMD response. While
303 in endothelium and microglia, the fold change remain similar between DE tests for two AMD stage
304 indicating a consistent AMD response for these two cell types.

305

306 **Enhanced AMD response in macula.** Similarly, to compare AMD response across retinal regions for,
307 we compared fold changes between normal vs. late AMD calculated using UAB macula and periphery
308 data:

309
$$y_g^j = \beta^j x_g^j + \varepsilon_g^j \quad g \in G_j$$

310 where y_g^j is log fold changes of gene g between normal vs, late AMD at cell type j calculated using
311 macula data, while x_g^j is the log fold change calculated using periphery data. The β^j reflects the overall
312 changes of DE effect size between retinal regions for cell type j . In the analysis, p values were adjusted
313 for the number of cell types using BH method. For each of the cell types, we reported estimated β and
314 its significance in the **Supplementary Fig. 9**. Significant β (adjusted P value < 0.05) were identified for
315 astrocytes, cone, endothelium, microglia, pericytes and rod. We noticed a larger fold changes in neuron
316 cell types including cone ($\beta=0.04$), horizontal ($\beta=0.0005$) and rod ($\beta=0.0028$).

317

318 **Consistent AMD response in periphery between datasets.** To compare AMD response in periphery
319 retina across different datasets, we compared fold changes and between MGS 4 vs, MGS 1 calculated
320 using EyeGEx periphery data, and between normal vs. late AMD calculated using UAB periphery:


321
$$y_g^j = \beta^j x_g^j + \varepsilon_g^j \quad g \in G_j$$

322 where y_g^j is log fold changes of gene g between normal vs. late AMD at cell type j calculated using UAB
323 periphery data, while x_g^j is the log fold change between MGS 4 vs. MGS 1 calculated using EyeGEx
324 periphery data. In the analysis, p values were adjusted for the number of cell types using BH method.
325 For each of the cell types, we reported estimated β and its significance in the **Supplementary Fig. 10**.
326 Significant (adjusted P value < 0.05) associate between fold changes estimated in different datasets
327 were observed for all cell types that have large number of ctDEGs detected, including microglia,
328 endothelium, astrocytes and pericytes. While such association are not significant for amacrine, Müller
329 glia and rods which possibly due to the lower level-AMD response in periphery for these cell types. The
330 result reveals the consistency between two periphery retina datasets.

331

332

EyeGEx Periphery



333

334

335

336 **Supplementary Fig. 8. Comparison of ctDEGs effect between AMD stages.** The scatter plots shows
337 the comparison of effect size of ctDEGs identified from two test: MGS 2 vs.1 and MGS 4 vs. 1. For each
338 of the cell types, regression was performed to investigate the possible linear relationship
339 (**Supplementary Note 7**). Coefficients (coef) and adjusted p values (padj) for the linear regression were
340 annotated on the plots.


341

342

343

344

UAB data



345

346

347

348 **Supplementary Fig. 9. Comparison of ctDEGs effect between retina regions.**

349 The scatter plots shows the comparison of effect size of ctDEGs identified from macula and periphery.

350 For each of the cell types, regression was performed to investigate the possible linear relationship

351 (**Supplementary Note 7**). Coefficients (coef) and adjusted p values (padj) for the linear regression were


352 annotated on the plots.

353

354

355

Comparison of two datasets



356

357

358

359 **Supplementary Fig. 10. Comparison of ctDEGs effect between periphery retina datasets.**

360 The scatter plots shows the comparison of effect size of ctDEGs identified from different periphery retina

361 datasets. For each of the cell types, regression was performed to investigate the possible associations

362 (**Supplementary Note 7**). Coefficients (coef) and adjusted p values (padj) for the linear regression were

363 annotated on the plots.

364 **Supplementary Data**

365

366 **Supplementary Data 1. Cell type-specific gene markers detected from the scRNA-seq data.**

367 a. Cell type-specific gene markers detected using combined data

368 b. Cell type-specific gene markers detected using macula data

369 c. Cell type-specific gene markers detected using periphery data

370

371 **Supplementary Data 2. Single-cell level expression patterns of AMD risk genes.**

372

373 **Supplementary Data 3. Differential expression results for the UAB bulk RNA-seq data.**

374

375 **Supplementary Data 4. ctDEGs identified in the EyeGEx bulk RNA-seq data.**

376 a. ctDEGs identified between MGS2 vs. MGS1

377 b. ctDEGs identified between MGS3 vs. MGS1

378 c. ctDEGs identified between MGS4 vs. MGS1

379

380 **Supplementary Data 5. GO enrichment result for ctDEGs in the EyeGEx bulk RNA-seq data.**

381

382 **Supplementary Data 6. ctDEGs identified in the UAB bulk RNA-seq data.**

383 a. ctDEGs identified between Early AMD vs. Normal in macula

384 b. ctDEGs identified between Late AMD vs. Normal in macula

385 c. ctDEGs identified between Early AMD vs. Normal in periphery

386 d. ctDEGs identified between Late AMD vs. Normal in periphery

387

388 **Supplementary Data 7. GO enrichment result for ctDEGs in the UAB bulk RNA-seq data.**

389

390 **Supplementary Data 8. Known retina cell type markers.**

391

392 **Supplementary References**

393

- 394 1. Choudhury, S. *et al.* Novel methodology for creating macaque retinas with sortable
395 photoreceptors and ganglion cells. *Front. Neurosci.* **10**, 551 (2016).
- 396 2. Butler, A., Hoffman, P., Smibert, P., Papalexi, E. & Satija, R. Integrating single-cell
397 transcriptomic data across different conditions, technologies, and species. *Nat. Biotechnol.* **36**,
398 411 (2018).
- 399 3. Li, X. *et al.* Deep learning enables accurate clustering and batch effect removal in single-cell
400 RNA-seq analysis. *bioRxiv* 530378 (2019).
- 401 4. Curcio, C. A. *et al.* Human chorioretinal layer thicknesses measured in macula-wide, high-
402 resolution histologic sections. *Invest. Ophthalmol. Vis. Sci.* **52**, 3943–3954 (2011).
- 403 5. Curcio, C. A. *et al.* Subretinal drusenoid deposits in non-neovascular age-related macular
404 degeneration: morphology, prevalence, topography, and biogenesis model. *Retina* **33**, (2013).
- 405 6. Ramrattan, R. S. *et al.* Morphometric analysis of Bruch's membrane, the choriocapillaris, and
406 the choroid in aging. *Invest. Ophthalmol. Vis. Sci.* **35**, 2857–2864 (1994).
- 407 7. Zanzottera, E. C. *et al.* The Project MACULA retinal pigment epithelium grading system for
408 histology and optical coherence tomography in age-related macular degeneration. *Invest.*
409 *Ophthalmol. Vis. Sci.* **56**, 3253–3268 (2015).
- 410 8. Gangnon, R. E. *et al.* Severity of age-related macular degeneration in 1 eye and the incidence
411 and progression of age-related macular degeneration in the fellow eye: the Beaver Dam Eye
412 Study. *JAMA Ophthalmol.* **133**, 125–132 (2015).

413

414

415